The M plus is a new multifocal intraocular lens from Oculentis, which works in a fundamentally different way from current multifocal implants. It is suitable both for cataract patients and those considering clear lens extraction as a means of minimising spectacle wear.

Whilst several different forms of multifocal have been tried, many have proved disappointing because of the severity of side effects included glare, dazzle and halos around points of light.

The M plus has a revolutionary design allowing the many benefits of multifocality but without compromising quality of vision. In particular the lens design allows good contrast sensitivity which is vital, particularly in the older eye. The M plus also comes in two “near powers” allowing patients to choose whether or not they want to read comfortably with text held close or at arms length.

For further details please contact the Sapphire Team on 0845 652 2414.

March 2010

*** Trials of new wet AMD treatment ***

Exciting trials are underway on a new approach to the treatment of wet macular degeneration. Whilst injections of Avastin or Lucentis have been extremely effective in controlling the disease the treatment requires potentially multiple injections and many clinic visits. A new method of delivering a precise dose of radiotherapy has been perfected by NeoVista who are conducting trials to assess the effect of a single surgical procedure (using the controlled mild radiotherapy (brachytherapy)) as an alternative to multiple injections. A trial is now underway in several centres around the country taking those patients who have had a number of intravitreal injections but still have active disease. Further details are available on the NeoVista website www.neovistainc.com.